ArticleOphthalmology and therapy2025
The Impact of 3% Diquafosol Ophthalmic Solution on Tear Film and Corneal Nerve Density in Patients with Diabetes and Dry Eye Disease: A Randomized Controlled Study.
Article in Ophthalmology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05682547 (A Single Center, Randomized, Controlled Trial Comparing the Clinical Efficacy of 3% Diquafosol Tetrasodium and 0.1 % Hyaluronic Acid 0.1% in Diabetic Patients With Dry Eye Disease), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Single Center, Randomized, Controlled Trial Comparing the Clinical Efficacy of 3% Diquafosol Tetrasodium and 0.1 % Hyaluronic Acid 0.1% in Diabetic Patients With Dry Eye Disease
Who cites it
1 citing paper in PubMed.
- Diabetic dry eye: advances in pathogenesis, diagnostic strategies, and therapeutic approaches.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo investigate the effects of 3% diquafosol ophthalmic solution (DQS) on tear film and corneal nerve density in patients with diabetes and dry eye disease (DED).
methodsThis randomized study included 99 diabetic participants with DED who received either DQS therapy (n = 100 eyes) or 0.1% hyaluronic acid (HA) therapy (n = 98 eyes) six times daily for 8 weeks. All participants were examined at baseline, week 4 (4W), and week 8 (8W) for non-invasive tear breakup time (NITBUT), redness score (RS), meibomian gland quality (MGQ), tear meniscus height (TMH), corneoconjunctival staining score (CFS), meibomian gland expression (MGEx), corneal sensitivity (CS), corneal nerve fiber density (CNFD), corneal nerve branch density (CNBD), corneal nerve fiber length (CNFL), tear film lipid layer (TFLL), and ocular surface disease index (OSDI).
resultsAt 8W, significant improvements in TMH, MGQ, CFS, and OSDI were found in two groups, while the DQS therapy also had significant improvements in NITBUT, MGEx, CS, CNFD, CNBD, and CNFL. A comparison between the DQS group and HA group found in the mean NITBUT (9.00 ± 6.56 vs. 6.95 ± 4.49 s, P = 0.011), TMH (0.25 ± 0.08 vs. 0.21 ± 0.08 mm, P = 0.004), RS Score (1.19 ± 0.36 vs. 1.53 ± 0.44, P < 0.001), TFLL (2.40 ± 0.49 vs. 2.84 ± 0.42, P < 0.001), MGEx (1.11 ± 0.82 vs. 1.39 ± 0.59, P = 0.007), MGQ (1.63 ± 0.49 vs. 1.97 ± 0.62, P < 0.001), CFS (1.06 ± 0.88 vs. 1.67 ± 1.35, P = 0.014), CS (5.93 ± 0.22 vs. 5.77 ± 0.55, P = 0.010), OSDI (14.56 ± 11.28 vs. 23.46 ± 12.32, P < 0.001), CNBD (39.58 ± 20.17 vs. 32.75 ± 20.95 no./mm
conclusionsBoth DQS and HA can improve the tear film of patients with diabetes and DED. DQS is more effective in treating DED compared to HA. Additionally, DQS may be beneficial for diabetic dry eye patients with corneal nerve damage.
trial registrationClinicalTrials.gov identifier, NCT05682547.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.